Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for IMVT-1402 in Graves’ disease . The expected timing is based on the latest available company guidance and may change.
05/20/26:- GD trial remains on track, with topline data expected in 2027. 08/06/26:- GD topline data remains expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.